Skip to content

Michael Bloch

Partner

London

Bloch Michael
Michael Bloch

Partner

London

Michael has extensive experience in a wide range of corporate finance and equity capital markets transactions, including IPOs, public and private acquisitions and disposals and auction processes, and private equity transactions, frequently on a cross-border basis.

Michael has also spent seven months on secondment in the ECM business team at Credit Suisse, and has previously worked on secondment at ExxonMobil.

“Rising Star” IFLR1000 2019 (Equity Capital Markets)

“‘Very technically savvy,’ ‘easy to work with’ and ‘a good, safe pair of hands.’” Chambers UK 2020 (Equity Capital Markets)

"He is really impressive" Chambers UK 2021 (Capital Markets: Equity)

"He has good experience and he's a nice guy to deal with" Chambers UK 2021 (Capital Markets: Equity)

"Next Generation Partner" Legall 500 UK 2021 (Equity Capital Markets - Mid-High Cap)

Other noteworthy experience includes advising:

  • Kuwait Energy on its USD650m acquisition by United Energy Group by way of scheme of arrangement.
  • McCarthy & Stone on its GBP388m IPO on the premium main market of the London Stock Exchange (issuer's counsel)
  • Tullet Prebon on its reverse takeover acquisition of the global hybrid voice-broking and information business of ICAP plc.
  • Cobham on its GBP500m and GBP512m rights issues on the London Stock Exchange (issuer's counsel)
  • Equinity on its GBP317m IPO on the premium main market of the London Stock Exchange (underwriters counsel)
  • Circassia Pharmaceuticals ont its GBP580m IPO on the premium main market of the London Stock Exchange and GBP275m placing and open offer in connection with the acquisitions of Aerocrine and Prosonix (issuer's counsel).
  • Softcat on its GBP153m IPO on the premium main market of the London Stock Exchange (underwriter's counsel)
  • Spire Healthcare on its GBP842m IPO on the premium main market of the London Stock Exchange (underwriter's counsel)
  • Sensyne Health a digital healthcare company that develops regulated medical products and services using artificial intelligence, on its GBP225m IPO on the London Stock Exchange's AIM market.
  • Medopad on its Series A funding round to develop its healthcare technology data-capture platform.
 

News & insights

building

Publications: 30 JULY 2021

UK SPACs - FCA relaxes rules including presumption of suspension on announcement of business combination

With effect from 10 August 2021, the UK Financial Conduct Authority is implementing its Listing Rule changes and guidance for UK Special Purpose Acquisition Companies.

Read more
two deck chairs with view to the sea

News: 30 JUNE 2021

Allen & Overy advises TUI on successful upsizing of April convertible bonds through almost 190 million euros

Allen & Overy has advised global leading listed tourism group TUI AG on its successful tap offering of convertible bonds with an aggregate principal amount of c. 190 million euros.

Read more
Image of crowded street with union jack umbrella in crowd

Publications: 29 JANUARY 2021

UK Regulation post-Brexit - Adjusting to the landscape for UK equity capital market participants

With the EU and the UK having reached a free trade agreement which sets out a framework for the substantial agreements to be put in place to govern their future relationship and the UK having left the…

Read more
Latest thinking - Back to the future

Publications: 08 DECEMBER 2020

Brexit Podcast: Preparing for the end of the Brexit transition period - key points for issuers of shares

With Brexit proper fast approaching, UK listed issuers of shares need to ensure they are prepared for the end of the transition period. 

Read more

Office

London

Allen & Overy LLP
One Bishops Square
London
E1 6AD

View office →

Qualifications

Professional

Admitted as solicitor, England and Wales, 2006

Academic

MA (Oxon), History, University of Oxford, 2002

Dip. Law, Nottingham Law School, 2003

LPC, Nottingham Law School, 2004

Experience highlights

Recognition